Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07135427 · ClinicalTrials.gov registry record · Phase 4
Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency
A Phase 4 study of COPD and Alpha 1-Antitrypsin, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07135427: Recruiting Phase 4 study of COPD and Alpha 1-Antitrypsin, sponsored by University of Alabama at Birmingham.
NCT07135427 is a Phase 4 study of COPD and Alpha 1-Antitrypsin that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 30 participants, below the 2,418-participant average among 85 other COPD trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07135427, a Phase 4 study of COPD and Alpha 1-Antitrypsin, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to learn whether patients who have a genetic mutation in the genes that cause alpha 1 antitrypsin deficiency also have genetic variation in nearby genes that can increase risk for reduced immune function and respiratory infections. To investigate this hypothesis, we will compare immune responses to the 20-valent pneumococcal conjugate vaccine (PCV20, Pfizer) between participants who have one abnormal copy of the SERPINA1 gene and either no COPD exacerbations, vs those with 2 or more COPD exacerbations in the past year.
Primary Outcome
Pneumococcal antibody levels/function, total IgG levels, IgG subclass levels; magnitude of change from baseline
Conditions Studied
Interventions
- BIOLOGICAL 20-valent pneumococcal conjugate vaccine
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-09-03 |
| Est. Completion | 2027-06 |
| Phase | Phase 4 |
What NCT07135427 shows while recruiting
NCT07135427 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 2,418-participant average among 85 other COPD trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with COPD appearing as the primary indexed condition, and to 1 intervention - of which 20-valent pneumococcal conjugate vaccine is the first listed.
NCT07135427 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT07135427 about?
NCT07135427 is a clinical study titled "Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency". The goal of this study is to learn whether patients who have a genetic mutation in the genes that cause alpha 1 antitrypsin deficiency also have genetic variation in nearby genes that can increase risk for reduced immune function and respiratory infections. To investigate this hypothesis, we will c...
What is the current status of trial NCT07135427?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2025-09-03. Estimated completion is 2027-06.
What conditions does trial NCT07135427 study?
This clinical trial studies the following conditions: COPD, Alpha 1-Antitrypsin, Antibody Deficiency.
What interventions are being tested in trial NCT07135427?
The interventions under investigation include: 20-valent pneumococcal conjugate vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT07135427?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07135427 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COPD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07135427's enrollment target sits among peer trials
30 64th of 85 higher than 16 of 85 other COPD trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COPD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)
RECRUITING · Phase 4
-
Peak Inspiratory Flow and Dry Powder Inhaler Performance in COPD
COMPLETED · Phase 4
-
Static Lung Hyperinflation and Sympathetic Nerve Activity-Associated Large Artery Stiffness in COPD Patients
COMPLETED · Phase 4
-
Effect of Brovana and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 4
-
Airway Clearance for Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
COMPLETED · Phase 4
-
Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI